Evidence map›Paper›PMID 30670416›Full record

ArticleAntimicrobial agents and chemotherapy2019

Software for Dosage Individualization of Voriconazole: a Prospective Clinical Study.

William Hope, Gary Johnstone, Silvia Cicconi, Timothy Felton, Joanne Goodwin, Sarah Whalley, Anahi Santoyo-Castelazo, Virginia Ramos-Martin, Jodi Lestner, Leah Credidio and 5 more

Abstract read
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

William HopeAntimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom william.hope@liverpool.ac.uk.ORCID 0000-0001-6187-878X
Gary JohnstoneLiverpool Clinical Trials Unit, University of Liverpool, Liverpool, United Kingdom.
Silvia CicconiLiverpool Clinical Trials Unit, University of Liverpool, Liverpool, United Kingdom.
Timothy FeltonDivision of Infection, Immunity and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine, and Health, The University of Manchester, Manchester Academic Health Science Centre, Wythenshawe, Manchester, United Kingdom.
Joanne GoodwinAntimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
Sarah WhalleyAntimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
Anahi Santoyo-CastelazoAntimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
Virginia Ramos-MartinAntimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
Jodi LestnerAntimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
Leah CredidioRoyal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom.
Aaron DaneAntimicrobial Pharmacodynamics and Therapeutics, University of Liverpool, Liverpool, United Kingdom.
Daniel F CarrMRC Centre for Drug Safety Science, University of Liverpool, Liverpool, United Kingdom.
Munir PirmohamedRoyal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom.
Rahim SalimRoyal Liverpool Broadgreen University Hospital Trust, Liverpool, United Kingdom.
Michael NeelyLaboratory of Applied Pharmacokinetics, University of Southern California, Los Angeles, California, USA.

Funding

Department of Health CS/08/08/10Medical Research Council MR/L006758/1
6 · The paper itself

Abstract

Voriconazole is a first-line antifungal agent. Therapeutic drug monitoring is a standard of care. The best way to adjust dosages to achieve desired drug exposure endpoints is unclear due to nonlinear and variable pharmacokinetics. Previously described software was used to prospectively adjust voriconazole dosages. The

Indexed as

Antifungal AgentsClinical Trials as TopicCytochrome P-450 Enzyme SystemFemaleGenotypeHumansMaleMiddle AgedProspective StudiesSoftwareVoriconazoleAntifungal AgentsCytochrome P-450 Enzyme SystemVoriconazoleantifungal agentsantifungal therapymathematical modelingpharmacokineticspopulation pharmacokineticssoftwarevoriconazole

Identifiers

PMID30670416
PMCPMC6496160

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.